RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
- Chemical Identification
- Environmental Hazards
- First Aid/Medical Treatment
- Handling/Storage/Shipping/Waste Management
- MSDS Documents
- Personal Protection
- Physical Hazards/Corrective Response Actions
- Physical/Chemical Properties
- Report Abstracts and Studies
- Reproductive Risk
- Toxicology/Health Hazards/Exposure
|Example of Acute Exposure data from MEDITEXT.|
RightAnswer Proprietary Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for 320-67-2:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- USES: Azacitidine is indicated for the treatment of various myelodysplastic syndrome subtypes including refractory anemia with or without ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
- PHARMACOLOGY: Appears to restore normal growth and differentiation of bone marrow cells by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. Hypomethylation may permit the normal functioning of genes that regulate differentiation and proliferation.
- EPIDEMIOLOGY: Overdoses are rare.
- WITH THERAPEUTIC USE
- COMMON: The most commonly occurring events (greater than 30%) following use include effects related to myelosuppression (ie, neutropenia, thrombocytopenia, anemia), fatigue, pyrexia, gastrointestinal symptoms (ie, nausea, vomiting, constipation or diarrhea), injection site reactions, petechiae, and hypokalemia.
- LESS FREQUENT: Other effects occurring less frequently include hypotension, myocarditis, mucositis, renal dysfunction, hepatic abnormalities, myalgias, rhabdomyolysis, headache, dyspnea, and coma.
- WITH POISONING/EXPOSURE
- MILD TO MODERATE TOXICITY: Gastrointestinal effects (nausea, vomiting, diarrhea) occurred following administration of a single IV dose of approximately 290 mg/m(2), approximately 4 times the recommended starting dose.
- SEVERE TOXICITY: Severe toxicity following overdose has not been reported. It is anticipated that clinical effects will likely be an extension of adverse events (ie, myelosuppression, fatigue, nausea, vomiting, diarrhea).
© 2011-2020 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.